By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
List view / Grid view
Filter the results
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.
Engineered deubiquitinases combines a synthetic nanobody that recognises a protein that can rescue proteins tagged for destruction.
Researchers have said that more COVID-19 studies should focus on the mucous membranes of the nose and mouth, to reveal insights into SARS-CoV-2 immunity.
A study in healthcare workers has shown that antibodies from COVID-19 infection protect individuals from reinfection for at least six months.
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
UKRI will provide £4 million in funding to establish a data infrastructure for scientists in the UK to study antibodies from COVID-19 patient samples.
Scientists have developed a new antibody-drug conjugate (ADC), made from ICAM1, an antibody that targets pancreatic cancer and the cytotoxic drug DM1 (mertansine).
Researchers have found antibodies, from infection with common cold coronaviruses, can also target SARS-CoV-2 - especially in children.
Researchers have found that the level of antibodies in the serum of SARS-CoV-2 patients correlated with disease severity.
An analysis of SARS-CoV-2 has allowed researchers to identify epitopes recognised by a large fraction of COVID-19 patients, with 10 that could be targeted by antibodies.
Pre-clinical studies in cells and hamsters have shown that potent antibodies from COVID-19 patients can prevent infection from SARS-CoV-2.
Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how their dual targeting mechanisms of action may drive their emergence as the next generation of immuno-oncology drugs.
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…